Markets & Finance

CS First Boston Cuts Applera-Applied Biosystems Rating


CS First Boston downgraded Applera-Applied Biosystems (ABI) to hold from buy.

Analyst Meirav Chovav says she's concerned over the biotech instrument maker's ability to deliver on top-line and bottom-line growth targets. She notes her $422 million Q4 revenue estimate and $0.24 EPS estimate are below the company's guidance and consensus, but she's concerned there could still be a downside. She notes the company says its 10%-13% projected revenue growth over the next several quarters may be adversely impacted as major foreign currencies have continued to a decline.

Chovav is concerned about a slowdown in mass spectrometer orders, and continued weakness in the DNA-sequence analysis market. She sees $0.95 2001 EPS, and $1.08 EPS for 2002.


Best LBO Ever
LIMITED-TIME OFFER SUBSCRIBE NOW

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus